<?xml version="1.0" encoding="UTF-8"?>

<Composition xmlns="http://hl7.org/fhir">
  <id value="composition-drug-pq-risk"/>
  <meta>
    <profile value="http://hl7.org/fhir/uv/pharm-quality/StructureDefinition/Composition-drug-pq"/>
  </meta>
  <language value="en"/>
  <text>
    <status value="generated"/><div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: Composition composition-drug-pq-risk</b></p><a name="composition-drug-pq-risk"> </a><a name="hccomposition-drug-pq-risk"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-Composition-drug-pq.html">Composition - Drug PQ</a></p></div><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:">Product Note - Summary for Risk of Impurities</span></p><p><b>date</b>: 2023-10-01</p><p><b>author</b>: <a href="Organization-organization-drug-pq-ex1.html">Organization AAA Molybdenum Products, Inc.</a></p><p><b>title</b>: 3.2.P.2.2.4 - Summary for Risk of Impurities</p></div>
  </text>
  <status value="final"/>
  <type>
    <text value="Product Note - Summary for Risk of Impurities"/>
  </type>
  <subject>
    <reference value="MedicinalProductDefinition/medicinalproductdefinition-drug-product-pq-ex1"/>
  </subject>
  <date value="2023-10-01"/>
  <author>
    <reference value="Organization/organization-drug-pq-ex1"/>
  </author>
  <title value="3.2.P.2.2.4 - Summary for Risk of Impurities"/>
  <section>
    <text>
      <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml"><p>Text for the risk assessment of elemental impurities in the product</p></div>
    </text>
  </section>
</Composition>